ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives - MASSIMINO, MICHELE; STELLA, STEFANIA; TIRRÒ, ELENA; PENNISI, MARIA STELLA; VITALE, SILVIA RITA; PUMA, ADRIANA; ROMANO, CHIARA; DI GREGORIO, SANDRA; TOMARCHIO, CRISTINA; DI RAIMONDO, FRANCESCO; MANZELLA, LIVIA (Anticancer research, 2020)
Keywords: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Catalytic activity; Chromosomes; Chronic myeloid leukemia; Comorbidity; Drug dosages; Drug Resistance, Neoplasm - genetics; Effectiveness; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Gene Expression Regulation, Leukemic - drug effects; Health risks; Hematology; Humans; Imatinib; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Life span; Molecular modelling; Molecular Targeted Therapy; Mutation; Myeloid leukemia; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Proteins; Proto-Oncogene Proteins c-abl - antagonists & inhibitors; Proto-Oncogene Proteins c-abl - genetics; Stem cells; Treatment Outcome; Tyrosine; Tyrosine kinase inhibitors; CML; TKI; review; efficacy; resistance; BCR-ABL1